Chenyang Wang

Dr. Chenyang Wang

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2008 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
WWWalter R.T. Witschey
Walter R.T. Witschey
ABArijitt Borthakur
Arijitt Borthakur
MEMark A. Elliott
Mark A. Elliott
MFMatthew Fenty
Matthew Fenty
MSMatthew A. Sochor
Matthew A. Sochor
RRRavinder Reddy
Ravinder Reddy
Purpose: To develop a T1ρ‐prepared, balanced gradient echo (b‐GRE) pulse sequence for rapid three‐dimensional (3D) T1ρ relaxation mapping within the time constraints of a clinical exam (<10 minutes), examine the effect of acquisition on the measured T1ρ relaxation time and optimize 3D T1ρ pulse sequences for the knee joint and spine.Materials and Methods: A pulse sequence consisting of inversion recovery–prepared, fat saturation, T1ρ‐preparation, and b‐GRE image acquisition was used to obtain 3D volume coverage of the patellofemoral and tibiofemoral cartilage and lower lumbar spine. Multiple T1ρ‐weighted images at various contrast times (spin‐lock pulse duration [TSL]) were used to construct a T1ρ relaxation map in both phantoms and in the knee joint and spine in vivo. The transient signal decay during b‐GRE image acquisition was corrected using a k‐space filter. The T1ρ‐prepared b‐GRE sequence was compared to a standard T1ρ‐prepared spin echo (SE) sequence and pulse sequence parameters were optimized numerically using the Bloch equations.Results: The b‐GRE transient signal decay was found to depend on the initial T1ρ‐preparation and the corresponding T1ρ map was altered by variations in the point spread function with TSL. In a two compartment phantom, the steady state response was found to elevate T1ρ from 91.4 ± 6.5 to 293.8 ± 31 and 66.9 ± 3.5 to 661 ± 207 with no change in the goodness‐of‐fit parameter R2. Phase encoding along the longest cartilage dimension and a transient signal decay k‐space filter retained T1ρ contrast. Measurement of T1ρ using the T1ρ‐prepared b‐GRE sequence matches standard T1ρ‐prepared SE in the medial patellar and lateral patellar cartilage compartments. T1ρ‐preparedb‐GRE T1ρ was found to have low interscan variability between four separate scans. Mean patellar cartilage T1ρ was elevated compared to femoral and tibial cartilage T1ρ.Conclusion: The T1ρ‐prepared b‐GRE acquisition rapidly and reliably accelerates T1ρ quantification of tissues offset partially by a TSL‐dependent point spread function. J. Magn. Reson. Imaging 2008;28:744–754.

7 February 2017 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PDF file
CWChenyang Wang
Chenyang Wang
CKChristopher R. King
Christopher R. King
MKMitchell Kamrava
Mitchell Kamrava
KIKeisuke S. Iwamoto
Keisuke S. Iwamoto
ACAllen M. Chen
Allen M. Chen
MSMichael L. Steinberg
Michael L. Steinberg

1 August 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
CWChenyang Wang
Chenyang Wang
AKAmar U. Kishan
Amar U. Kishan
MKMitchell Kamrava
Mitchell Kamrava
MSMichael L. Steinberg
Michael L. Steinberg
CKChristopher R. King
Christopher R. King

1 October 2019 in Advances in Radiation Oncology
Verified
Journal Article
Open access
CWChenyang Wang
Chenyang Wang
AKAmar U. Kishan
Amar U. Kishan
JYJames B. Yu
James B. Yu
ARAnn Raldow
Ann Raldow
CKChristopher R. King
Christopher R. King
PKPatrick A. Kupelian
Patrick A. Kupelian
Second malignancies (SMs) after radiation therapy are rare but serious sequelae of treatment. This study investigates whether radiation therapy use is associated with changes in baseline SM risk. We extracted all patients with cancer, with or without SM, in the Surveillance, Epidemiology, and End Results database from 1973 to 2014. Cumulative incidence of SM for patients stratified by radiation therapy status was calculated using a competing risk model, both for the entire cohort and for subgroups based on the primary tumor's anatomic location. We identified 2,872,063 patients with cancer, including 761,289 patients who received radiation therapy and 2,110,774 who did not. The SM rate at 20 years for patients receiving radiation therapy versus no radiation therapy was 21.4% versus 18.8%. The relative risk for SM associated with radiation therapy for the overall group was 1.138 at 20 years. The relative risks for SM associated with radiation therapy to malignancies arising from central nervous system and orbits, head and neck, thorax, abdomen, and pelvis at 20 years were 0.704, 1.011, 0.559, 0.646, and 1.106 for men and 0.792, 1.298, 1.265, 0.780, and 0.988 for women, respectively. The association between SM and radiation therapy varies with both sex and disease anatomic location, with the largest increase in SM seen in females irradiated to the head and neck region. Overall, the absolute change in SM rates associated with radiation therapy remains small, with differences in various clinical contexts.

1 March 2018 in Brachytherapy
Verified
Journal Article
Closed access
CWChenyang Wang
Chenyang Wang
JRJagdeep Raince
Jagdeep Raince
USUma Swamy
Uma Swamy
SPSang-June Park
Sang-June Park
LZLalaine Zaide
Lalaine Zaide
MKMitchell Kamrava
Mitchell Kamrava

6 January 2017 in Cureus
Verified
Journal Article
Open access
CWChenyang Wang
Chenyang Wang
MKMitchell Kamrava
Mitchell Kamrava
CKChris King
Chris King
MSMichael L. Steinberg
Michael L. Steinberg
Introduction Race may be a significant factor that influences prostate cancer (PCa) survival, with the Asian (AsA) race being associated with better outcomes compared to African American (AA) and Non-Hispanic Whites (NHW). This study evaluates race-dependent variation in PCa-specific mortality (PCSM) associated with radiation dose-escalation exemplified by external beam radiotherapy (EBRT) with a brachytherapy (BT) boost in Gleason score 8-10 PCa. Methods 28,956 men diagnosed with clinically localized PCa and Gleason score 8-10 from 2004-2013 who received EBRT, EBRT with a BT boost, or radical prostatectomy (RP) were identified using the Surveillance, Epidemiology, and End Results (SEER) database. PCSM adjusted for age, diagnosis year, T-stage, Gleason scores, and treatment modalities was compared between races using a competing risk model that accounted for other-cause mortality (OCM). Results Compared to AsA, AA and NHW are associated with significantly increased PCSM with adjusted hazard ratios (AHR) of 2.295 and 1.989, respectively (p < 0.001 for both). In a subgroup analysis stratified by race, dose-escalation exemplified by EBRT with a BT boost in both AA and AsA failed to demonstrate a significant difference in PCSM compared to EBRT alone (p = 0.530 and 0.990, respectively), while a significant PCSM decrease was seen in NHW (p = 0.006). Conclusions Dose-escalation exemplified by EBRT with a BT boost had no significant effect on PCSM of AsA and AA, while it did decrease PCSM amongst NHW. Further evaluation of race as a factor impacting PCSM in the era of dose-escalation is needed in the prospective setting.